Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Syros Pharmaceuticals (SYRS)

Syros Pharmaceuticals (SYRS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 331,889
  • Shares Outstanding, K 42,441
  • Annual Sales, $ 2,050 K
  • Annual Income, $ -62,280 K
  • 60-Month Beta 1.59
  • Price/Sales 131.45
  • Price/Cash Flow N/A
  • Price/Book 3.82

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.47
  • Number of Estimates 5
  • High Estimate -0.38
  • Low Estimate -0.59
  • Prior Year -0.54
  • Growth Rate Est. (year over year) +12.96%

Price Performance

See More
Period Period Low Period High Performance
1-Month
6.53 +25.65%
on 12/23/19
9.41 -12.81%
on 01/15/20
+1.17 (+16.71%)
since 12/20/19
3-Month
4.45 +84.38%
on 12/10/19
9.41 -12.81%
on 01/15/20
+2.42 (+41.96%)
since 10/22/19
52-Week
4.45 +84.38%
on 12/10/19
11.93 -31.22%
on 09/13/19
+1.30 (+18.74%)
since 01/22/19

Most Recent Stories

More News
Can The Uptrend Continue for Syros Pharmaceuticals?

As of late, it has definitely been a great time to be an investor Syros Pharmaceuticals

SYRS : 8.20 (+4.92%)
Syros Announces Strategic Priorities and Expected Milestones

--Mature Data for SY-1425 in Combination with Azacitidine in RARA-Positive Newly Diagnosed Unfit AML Patients Expected in Fourth Quarter of 2020

SYRS : 8.20 (+4.92%)
Syros Announces Appointment of Mark Alles to Its Board of Directors

Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, today announced the appointment of Mark Alles to the Company's Board of Directors. Mr....

CELGZ : 0.47 (+2.15%)
SYRS : 8.20 (+4.92%)
Flagship Unveils Newest Pioneering Platform: Ring Therapeutics

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the launch of Ring Therapeutics, an early-stage biotechnology company developing first-in-class gene therapies using a...

AXLA : 5.08 (+0.40%)
DNLI : 23.40 (+6.32%)
EVLO : 5.37 (+16.23%)
KLDO : 5.74 (+4.55%)
MRNA : 21.97 (+4.92%)
RUBY : 8.55 (+0.59%)
MCRB : 3.45 (+0.88%)
SYRS : 8.20 (+4.92%)
GBT Secures $150 Million Non-Dilutive Term Loan Financing

Balance Sheet Strengthened to Support Pipeline Advancement and Oxbryta(TM) (voxelotor) Commercialization

GBT : 80.83 (-1.51%)
SYRS : 8.20 (+4.92%)
GBT and Syros Partner to Discover, Develop and Commercialize Novel Therapies for Sickle Cell Disease and Beta Thalassemia

Collaboration Combines GBT's Therapeutic Area Leadership with Power of Syros' Gene Control Platform

GBT : 80.83 (-1.51%)
SYRS : 8.20 (+4.92%)
Flagship Pioneering Strengthens Leadership With Appointment of Paul Biondi as Executive Partner

Flagship Pioneering, a unique life sciences innovation enterprise, today announced the appointment of Paul Biondi to the post of Executive Partner. Mr. Biondi most recently served as Senior Vice President,...

BMY : 67.43 (unch)
AXLA : 5.08 (+0.40%)
DNLI : 23.40 (+6.32%)
EVLO : 5.37 (+16.23%)
KLDO : 5.74 (+4.55%)
MRNA : 21.97 (+4.92%)
RUBY : 8.55 (+0.59%)
MCRB : 3.45 (+0.88%)
SYRS : 8.20 (+4.92%)
Syros Presents on Identification of Novel Fetal Hemoglobin Repressor as Part of Broader Drug Discovery Program in Sickle Cell Disease at 61st Annual ASH Meeting

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that it has discovered and validated a novel fetal hemoglobin repressor,...

SYRS : 8.20 (+4.92%)
Flagship Pioneering Names Dr. Nancy Simonian, CEO of Syros, as Recipient of the 2019 Pioneering Leader Award

Flagship Pioneering has announced the recipient of the firm's annual Pioneering Leader Award. The 2019 award recognizes Nancy Simonian, M.D., CEO of Syros Pharmaceuticals (NASDAQ: SYRS), a company that...

AXLA : 5.08 (+0.40%)
DNLI : 23.40 (+6.32%)
EVLO : 5.37 (+16.23%)
KLDO : 5.74 (+4.55%)
MRNA : 21.97 (+4.92%)
RUBY : 8.55 (+0.59%)
MCRB : 3.45 (+0.88%)
SYRS : 8.20 (+4.92%)
Syros to Present at Piper Jaffray 31st Annual Healthcare Conference

Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., will participate...

SYRS : 8.20 (+4.92%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade SYRS with:

Business Summary

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. It focuses on treatments for cancer and immune-mediated diseases as well as building a pipeline of gene control medicines. The company's product pipeline includes SY-1425, a selective RARa agonist for genomically defined subsets of patients...

See More

Key Turning Points

2nd Resistance Point 8.60
1st Resistance Point 8.40
Last Price 8.20
1st Support Level 7.87
2nd Support Level 7.53

See More

52-Week High 11.93
Fibonacci 61.8% 9.07
Last Price 8.20
Fibonacci 50% 8.19
Fibonacci 38.2% 7.31
52-Week Low 4.45

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar